|
Market Closed -
Nasdaq
02:30:00 14/02/2026 am IST
|
5-day change
|
1st Jan Change
|
|
148.75 USD
|
+1.77%
|
 |
-0.74%
|
-14.53%
|
|
28/01 |
Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target
|
MT
| |
23/01 |
Roth Capital Initiates Coverage on Insmed With Buy Rating, $212 Price Target
|
MT
| |
21/01 |
RBC Raises Price Target on Insmed to $200 From $197, Keeps Outperform Rating
|
MT
| |
08/01 |
RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating
|
MT
| |
06/01 |
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating
|
MT
| |
18/12 |
Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says
|
MT
| |
18/12 |
Mizuho Adjusts Price Target on Insmed to $212 From $256, Maintains Outperform Rating
|
MT
| |
18/12 |
RBC Lowers Price Target on Insmed to $195 From $215, Keeps Outperform Rating
|
MT
| |
18/12 |
Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron…
|  | |
04/12 |
Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target
|
MT
| |
01/12 |
Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating
|
MT
| |
31/25/31 |
Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says
|
MT
| |
31/25/31 |
RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating
|
MT
| |
31/25/31 |
UBS Adjusts Insmed Price Target to $223 From $194, Maintains Buy Rating
|
MT
| |
31/25/31 |
Truist Raises Price Target on Insmed to $214 From $139, Keeps Buy Rating
|
MT
| |
31/25/31 |
Analyst recommendations: Comcast, Roblox, Alphabet, Reddit, Western Digital…
| | |
17/25/17 |
Insmed Incorporated CHMP Recommends EU Approval of Brinsupri (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
|
CI
| |
14/25/14 |
UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating
|
MT
| |
08/25/08 |
RBC Lifts Price Target on Insmed to $139 From $138, Keeps Outperform Rating
|
MT
| |
03/25/03 |
Analyst recommendations: Coinbase, Corteva, PayPal, Coreweave…
| | |
02/25/02 |
Analyst recommendations: Corteva, Dell, Electronic Arts, Nike, Apple…
| | |
03/25/03 |
Analyst recommendations: Accenture, Chipotle, Kraft, Lucid Group, Thor Industries…
| | |
21/25/21 |
Morgan Stanley Raises Price Target on Insmed to $144 From $126, Keeps Equalweight Rating
|
MT
| |
20/25/20 |
William Blair Initiates Insmed at Outperform
|
MT
| |
20/25/20 |
Analyst recommendations: Intel, Roblox, Circle Internet, Insmed Inc, The Hershey Company…
| |
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
